Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 4/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 11/20 | 0.39 |
| ▸ | JAK2 | O60674 | 10/20 | 0.39 |
| ▸ | JAK3 | P52333 | 10/20 | 0.39 |
| ▸ | TYK2 | P29597 | 9/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10124999 | 0.91 | NUDT1 (0.50) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL12346646 | 0.88 | NUDT1 (0.51) | NUDT1CITROCK1JAK2JAK3 | |
| SCHEMBL10125205 | 0.86 | NUDT1 (0.48) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL1718573 | 0.84 | NUDT1 (0.46) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL10124992 | 0.80 | NUDT1 (0.49) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL10125181 | 0.78 | NUDT1 (0.47) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL10125127 | 0.76 | NUDT1 (0.57) | NUDT1CITROCK1JAK1JAK2 | |
| SCHEMBL10125534 | 0.75 | NUDT1 (0.55) | NUDT1CITROCK1JAK2JAK3 | |
| SCHEMBL1717982 | 0.72 | NUDT1 (0.62) | NUDT1CITROCK1JAK2JAK3 | |
| SCHEMBL10125174 | 0.72 | NUDT1 (0.49) | NUDT1CITROCK1JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | NUDT1 2466/4885CIT 54/4885ROCK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.